Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
© 2018 British Society for Haematology and John Wiley & Sons Ltd..
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventy-eight patients were enrolled (median age 63·5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow-up of 15·2 months, median progression-free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment-emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
British journal of haematology - 184(2019), 4 vom: 20. Feb., Seite 536-546 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Shaji K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.12.2019 Date Revised 27.12.2019 published: Print-Electronic ClinicalTrials.gov: NCT02046070 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.15679 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290922631 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290922631 | ||
| 003 | DE-627 | ||
| 005 | 20231225065752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.15679 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0969.xml |
| 035 | |a (DE-627)NLM290922631 | ||
| 035 | |a (NLM)30460684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2019 | ||
| 500 | |a Date Revised 27.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02046070 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventy-eight patients were enrolled (median age 63·5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and <65 years (25% and 16% ≥VGPR), respectively. At a median follow-up of 15·2 months, median progression-free survival (PFS) was 14·2 months, with a trend towards better PFS in patients aged ≥65 years vs. <65 years (median 18·7 months vs. 12·0 months; hazard ratio 0·62, P = 0·14). ICd was well tolerated. The most common treatment-emergent adverse events were diarrhoea (33%), nausea (24%), upper respiratory tract infection (24%), and thrombocytopenia (22%); 10 patients (13%) had peripheral neuropathy (one grade 3). This study is registered at ClinicalTrials.gov (NCT02046070) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ixazomib | |
| 650 | 4 | |a proteasome inhibitor | |
| 650 | 4 | |a relapsed myeloma | |
| 650 | 4 | |a response | |
| 650 | 4 | |a survival | |
| 650 | 7 | |a Boron Compounds |2 NLM | |
| 650 | 7 | |a ixazomib |2 NLM | |
| 650 | 7 | |a 71050168A2 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Glycine |2 NLM | |
| 650 | 7 | |a TE7660XO1C |2 NLM | |
| 700 | 1 | |a Grzasko, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Delimpasi, Sosana |e verfasserin |4 aut | |
| 700 | 1 | |a Jedrzejczak, Wieslaw W |e verfasserin |4 aut | |
| 700 | 1 | |a Grosicki, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Kyrtsonis, Marie-Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Zhaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Byrne, Catriona |e verfasserin |4 aut | |
| 700 | 1 | |a Labotka, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 184(2019), 4 vom: 20. Feb., Seite 536-546 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2019 |g number:4 |g day:20 |g month:02 |g pages:536-546 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.15679 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2019 |e 4 |b 20 |c 02 |h 536-546 | ||